⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025Open Access

Supplemental Figure 9 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Leanne G. Ahronian Soumyadip Sahu Minjie Zhang Ayushi S. Patel Ke Geng Reshmee Bhattacharya Gerald S. Falchook Jonathan W. Goldman Alexander I. Spira Salman R. Punekar David R. Spigel Judy S. Wang Ferdinandos Skoulidis Janaye Stephens Mary Meynardie Jaylen M. Powell Alfonso Lopez Michela Ranieri Magdalena A. Ploszaj Yi Jer Tan Yeuan Ting Lee Yi Yu Jiehui Deng Ting Chen Patrick McCarren Alice Tsai Suleman S. Hussain Brian Doyon Kenjie Amemiya Jacques Ermolieff Preksha Shahagadkar Nikitha M. Das Lauren R. Flynn Julie A. Shields Laney Danielczyk Brian J. McMillan Andre Mignault Samuel R. Meier Hsin‐Jung Wu David J. Guerin Douglas A. Whittington Chengyin Min Iga Sienczylo John P. Maxwell Heather DiBenedetto Hideo Watanabe Brian B. Haines Alan Huang Adam Crystal Jannik N. Andersen Xinyuan Wu Kwok‐Kin Wong

View Full Paper

Ask AI

Bookmark

Share

Key Points

TNG260 treatment sensitizes STK11-mutant tumors to anti-PD-1 immunotherapy, improving treatment outcomes.
No significant change in intratumoral Treg cell proportions following TNG260 administration was observed.
The study involved evaluating the effects of a small-molecule CoREST inhibitor in specific tumors.
These findings suggest potential strategies for enhancing immunotherapy effectiveness in genetically defined tumor populations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

TNG260 treatment enhances response to anti-PD-1 in STK11-mutant tumors without altering Treg cells.

Abstract

TNG260 treatment does not affect proportion of intratumoral Treg cells

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahronian et al. (2025) studied this question.

synapsesocial.com/papers/68f199c5de32064e504dcda8 https://doi.org/10.1158/0008-5472.30363280

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
2Supplemental Figure 7 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
3Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
4Supplemental Figure 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
5Supplemental Table 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
6Supplemental Table 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
7Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
8Supplemental Table 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025